TransGenic Group

TransGenic Group Equity

The The Equity of TransGenic Group (2342.T) as of Nov 16, 2026 is 4.78 B JPY. In the previous year, The Equity was 4.76 B JPY — a change of 0.37% (higher).

Equity

4.78 BJPY

YoY

0.37%

Last updated:

In 2026, TransGenic Group's equity was 4.78 B JPY, a 0.37% increase from the 4.76 B JPY equity in the previous year.

The TransGenic Group Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
4.89 B JPY
Jan 1, 2020
4.42 B JPY
Jan 1, 2021
4.92 B JPY
Jan 1, 2022
6.53 B JPY
Jan 1, 2023
6.02 B JPY
Jan 1, 2024
5.89 B JPY
Jan 1, 2025
4.76 B JPY
Jan 1, 2026
4.78 B JPY
The TransGenic Group Equity history
YEAREquityYoY
4.78 BJPY+0.37%
4.76 BJPY-19.20%
5.89 BJPY-2.06%
6.02 BJPY-7.88%
6.53 BJPY+32.88%
4.92 BJPY+11.32%
4.42 BJPY-9.62%
4.89 BJPY+12.55%
4.34 BJPY+36.82%
3.17 BJPY+3.37%
3.07 BJPY+10.53%
2.78 BJPY+2.39%
2.71 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing TransGenic Group's Equity

TransGenic Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding TransGenic Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating TransGenic Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

TransGenic Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in TransGenic Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about TransGenic Group stock

The Equity of TransGenic Group is 4.78 B JPY in 2026.

The Equity of TransGenic Group changed from 4.76 B JPY to 4.78 B JPY, representing a 0.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TransGenic Group

All Key Metrics — TransGenic Group